Loading…
← CockpitCompetitor Analysis › 7701.T Shimadzu CorporationOpen in the cockpit ↗

Shimadzu Corporation7701.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Makes scientific and analytical instruments, including mass spectrometers, plus medical imaging equipment.

≈ A smaller Agilent/Thermo FisherMomentum leader 82
Mkt cap
$8.14B
US dollars, full cap
Free float
79%
of shares outstanding
$/day
$34.7M
20-day average traded
Fwd P/E
21.0×
forward earnings
ROIC−WACC
+2.4 pp
WACC 7.4%
Hurdle
+1 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · JPY¥4,353
1D-1.1%
1W-5.5%
1M-0.1%
3M+3.1%
6M+24.2%
YTD+4.4%
1Y+4.0%
ATR %2.8%
52w lowhigh7.6% off high

What Shimadzu does

Makes scientific and analytical instruments, including mass spectrometers, plus medical imaging equipment.

Sells analytical instruments to labs and then supplies recurring service and consumables, such as columns and replacement parts, for the installed base. Separate businesses cover x-ray imaging for hospitals, aircraft equipment and industrial machinery. A large share of sales comes from outside Japan.

In one line: A smaller Agilent/Thermo Fisher.

Products and services

  • Mass spectrometers/chromatographs
  • Medical diagnostic imaging
  • Industrial/aerospace equipment

Customers

  • Research labs/universities
  • Pharmaceutical/biotech companies
  • Hospitals

Where it sits in the supply chain

  • Scientific instruments
  • Analytical instrument manufacturing
  • Mass spectrometers, medical imaging

What could go right

  • Life sciences/pharma R&D spending

What could go wrong

  • Research funding cyclicality

Moat: narrow (process know-how, installed base). Precision analytical-instrument expertise and installed base drive recurring service/consumables.

Headquarters: Kyoto, Japan · Founded: 1875 · Employees: 14,649

Named competitors

Shimadzu at a glance

Size Shimadzu (7701.T) is a Japan Health Care company (Medical Specialties) with a market value of $8.14B, the 169th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,353 on 18 Nov 2026.

Performance Over six months the shares gained 24.2%, against +27.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 7.8% over the last twelve months (peer median +3.4%); the operating margin is 13.6% (peer median 18.0%).

Valuation It trades at 21.0× forward earnings against a peer median of 20.3× (11th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.4 points above its cost of capital (7.4% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026Peer median 1297701.T 121
Six months, rebased to 100: Shimadzu against the median of its 20 peers (local-currency closes).

Shimadzu financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥586B¥561B¥539B¥512B¥482B
Revenue growth—+4%+5%+6%—
Gross profit¥266B¥250B¥234B¥221B¥201B
EBITDA¥101B¥95.0B¥92.4B¥91.9B¥86.1B
Net income¥65.1B¥60.5B¥53.8B¥57.0B¥52.0B
Free cash flown/a¥39.7B¥36.9B¥14.6B¥31.5B
Capital expendituren/a¥14.9B¥15.1B¥15.5B¥16.8B
Total debt¥121B¥10.5B¥11.7B¥11.9B¥11.3B

Quarterly statements and history in the cockpit →

Shimadzu competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%+20%6869300832GETI-BBLCO7747GMEDBRKRYPSNPODDCTECCOHLNTHBIOTFXQGENDEMANTAVTR688617COOALGN7701.T6-month return →1-month return →
Up and to the right = strong over both horizons. Shimadzu is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%20×30×6869300832GETI-BBLCO7747GMEDBRKRYPSNPODDCTECCOHLNTHBIOTFXQGENDEMANT688617COOALGN7701.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shimadzu is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6869300832GETI-BBLCO7747GMEDBRKRPODDCTECCOHLNTHBIOTFXQGENDEMANTAVTR688617COO7701.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shimadzu is the large dot.

Shimadzu competitors and peer comparison

Head to head with its named competitors (7701.T vs TMO vs A vs 6869.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shimadzu 7701.T$8.14B+24%+8%14%21.0×8.3%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Agilent Technologies A$50.0B+56%+9%24%27.0×23.3%
Sysmex 6869.T$8.06B+58%+8%13%32.0×4.4%

How Shimadzu compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shimadzu against its 20 peers (data as of 18 Nov 2026)
Measure7701.TPeer medianRank in peer set
1-month return-0.1%+9.4%5th lowest of 21
6-month return+24.2%+27.8%9th lowest of 21
Distance from 52-week high-7.6%-8.2%10th highest of 21
Revenue growth (TTM)+7.8%+3.4%8th highest of 21
Operating margin13.6%18.0%8th lowest of 21
Forward P/E21.0×20.3×11th cheapest of 21
Growth the price implies (Req g, 7 yrs)8.3%10.6%7th least demanding of 20
Growth delivered (Del g)+7.3%+10.3%7th lowest of 20
Hurdle (Req g minus delivered)+0.9 pp+1.8 pp10th least demanding of 20
ROIC minus cost of capital+2.4 pp+2.8 pp9th lowest of 21
EV / EBITDA12.7×14.5×6th cheapest of 19
Net debt / EBITDA-0.1×1.1×6th least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%

Questions

Who are Shimadzu's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Agilent Technologies (A), Sysmex Corp (6869.T). The cockpit's measured peer set (industry) also includes Sysmex (6869.T), Shenzhen New Industries Biomedical Engineering (300832.SZ), Getinge (GETI-B.ST), Bausch + Lomb (BLCO.TO), Asahi Intecc (7747.T), Globus Medical (GMED).
Is Shimadzu expensive compared with its peers?
On forward p/e it trades at 21.0× against a peer median of 20.3×, 11th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shimadzu stock performed?
Over six months to 18 Nov 2026 the shares returned +24.2% against +27.8% for the median peer; over one year +4.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.